In conclusion, the combined activation of the MAPK pathway, predominantly through BRAF p.V600E, coupled with the CDKN2A/B deletion, firmly establishes itself as the molecular signature of PXA. Here, CDKN2A is linked to pleomorphic xanthoastrocytoma.